The findings indicate improvements in mental and physical health as well as reductions in health care costs for people with type 1 diabetes.
San Diego, June 24, 2023 /PRNewswire/ — Results of two studies evaluating the impact of mental health support for patients with diabetes found significant benefits on patient outcomes were presented today at 83.rd American Diabetes Association Scientific Sessions® (ADA) by San Diego, California
As the number of people with diabetes increases, addressing mental health challenges is an important part of helping individuals with diabetes manage their care plans. Diabetes mellitus (DD), for example, includes the risks, stresses and burdens associated with diabetes. DD, which differs from depression, is common in adults with type 1 diabetes (T1D). In fact, in any 18 month term, 33% to 50% People with diabetes have a higher DD. So are individuals with diabetes They are 2 to 3 times more likely to have depression than people with diabetes. In addition to that, Only 25% to 50% People with diabetes are known to be depressed. This suggests the need to provide proactive behavioral health support as part of a comprehensive plan of care.
“People with type 1 diabetes are at increased risk for mental health issues, including diabetes anxiety, depression, anxiety and disordered eating. However, these are all treatable health conditions that go beyond physical symptoms and can be managed with personalized treatment plans,” he said. Robert Gabby, MD, PhD, ADA’s Chief Scientific and Medical Officer. “I am encouraged by the findings from the research presented at this year’s Scientific Sessions as we continue to search for new, evidence-based solutions to support people with diabetes when they need it most.”
The EMBARK clinical trial: reducing the emotional burdens of living with diabetes
Results of the randomized, controlled EMBARK clinical trial showed significant reductions in DD in adults with T1D across three intervention programs.
The EMBARK trial included 300 adults with T1D and elevated anxiety. Individuals were randomly assigned to receive one of three intervention programs: (1) Streamline, a teacher-led learning and management program; (2) TunedIn, a psychologist-led program focused exclusively on reducing diabetes. or (3) FixIt, a combination of the StreamLine and TunedIn programs. Each intervention takes place in a group-based, virtual format over three to four months, including initial workshops, one-on-one phone calls, and follow-up meetings.
Results showed large and clinically meaningful reductions in DD in all three study arms, with 35% of participants no longer reporting elevated levels of anxiety at follow-up and 74% of participants reporting clinically important reductions in anxiety. . The FixIt intervention, which combined education and emotional DD-targeted approaches, resulted in the greatest reduction in DD, followed by TunedIn and Streamline. DD reductions were significantly greater in the FixIt intervention compared to Streamline.
“The initial results of the EMBARK trial are promising for people living with T1D who suffer from diabetes,” he said. Daniel Hessler JonesPhD, Professor and Vice Chair of Research in the Department of Family and Community Medicine University of California, San Francisco, and detective detective. “These findings highlight the importance of providing comprehensive support that meets the educational and emotional needs of individuals with diabetes.”
The authors of this study will report 12-month follow-up findings later this year to understand whether these improvements are associated with glycemic outcomes. Additionally, there are plans to expand on this work in DD-ASSIST, where researchers in a new study will train clinical teams from 18 diabetes clinics how to assess and address DD as part of their care.
A late-breaking poster: Do the right thing: behavioral intervention for at-risk T1D youth
Results from a study of home- and community-based behavioral health interventions for youth with diabetes showed that, in addition to improved health, patients had lower health care costs in the years after NICH.
The study evaluated direct cost data from three health care systems for youth with preventable health problems who received an intensive behavioral health intervention NICH. Youth with T1D and at least one year of cost data before and after NICH enrollment were included in the analysis. Outpatient, emergency department, and inpatient costs combined, with differences in the amount and type of cost data available across sites.
The analysis included 53 young people: mean age 14.2 ± 2.4 years; 87% Medicaid; 58% female, 42% male; 32% black, 29% non-Hispanic white, 28% Hispanic/Latinx, 7% Pacific Islander, 2% Asian, and 2% other racial and ethnic groups. Average annual direct costs were $58.1 thousand And 21.8 thousand dollarsBefore and after NICH registration, respectively, but not separately. After removing three outliers (>3 SD from the mean), the average annual costs decreased significantly $20.4k to the $9.5k At a young age, mostly due to patient fees.
“These results highlight the benefits of intensive interventions for pediatric patients with health disparities,” he said. David V. Wagner, PhD and senior author. “Investing in health disparities early in young people’s lives is not only the right thing to do to improve patient health, but it can also have a positive economic impact down the road.”
Researchers are designing ongoing studies and related efforts to further expand the reach of this intervention nationwide and determine its impact on the life experiences of people with diabetes.
Study Presentation Details:-
Dr. Hessler will present his findings in the following oral presentation session:
- ADA Presidents’ Select Summary: EMBARK—a randomized, controlled trial comparing three approaches to reducing diabetes stress in adults with type 1 diabetes
- presented on Saturday June 24, 2023 as if 4:30 PM PST
Dr. Wagner will present his findings in the following general poster session:
- Do the Right Thing—High Intervention and High Social Risk Youth and the Costs of Type 1 Diabetes (T1D)
- presented on Saturday June 24, 2023 as if 11:30 am PST
Scientific sessions about the ADA
83 of the ADArd The scientific sessions of the world’s largest scientific meeting focused on diabetes research, prevention and care will be held in San Diego, California On June 23-26. More than 12,000 renowned physicians, scientists, and health care professionals from around the world are expected to unveil the latest research, treatment recommendations, and advances in the physical and virtual cures for diabetes. Attendees will gain exclusive access to thousands of original research presentations and engage in stimulating and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADA2023.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people with diabetes thrive. For 82 years, the ADA has made breakthroughs and research into medicine to treat, manage, and prevent diabetes. Through advocacy, program development and education, we aim to improve the quality of life for the more than 133 million Americans living with diabetes or pre-diabetes. Diabetes brings us together. What we do next keeps us connected for life. To learn more or get involved, visit us at Diabetes.org Or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (American Diabetes AssociationLinkedInAmerican Diabetes Association), Twitter (@AmDiabetesAssnand Instagram (@AmDiabetesAssn).
Contact: Rebecca Fisher703-253-4918
Source American Diabetes Association